Tag Archive for: mcrpc
Personalized Treatment for Advanced Prostate Cancer: The Power of Multi-Tracer PET Imaging
/in Preclinical Research/by MaxPhase 2 trial: Delaying Systemic Treatment in Metastatic Prostate Cancer – A New Approach
/in Clinical Trial, Metastatic, Phase 2/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 3/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxDarolutamide Plus ADT: A Great Treatment Option for Metastatic Hormone-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- New PSMA Radiohybrid Combines PET Imaging With Alpha Therapy October 14, 2026
- Phase 2 Trial Tests Tinengotinib With Darolutamide or Enzalutamide in Hormone-Resistant Prostate Cancer October 13, 2026
- Phase 1 Trial Investigates MAO-A Inhibition With ITR-251 to Overcome Prostate Cancer Resistance October 13, 2026
- Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer October 13, 2026